Selected predictors increase the chance of effective interferon beta treatment in patients with multiple sclerosis
Keywords:
predictors, multiple sclerosis, interferon beta, outcomeAbstract
Background: Most demographic, clinical and MRI variables in patients with relapsing – remitting multiple sclerosis (RRMS) failed to predict the IFN beta treatment outcome.
Objective: To identify pre-treatment and early treatment variables which predict in RRMS patients a beneficial response to the INF beta therapy.
Method and patients: A survey of 20 articles on pretreatment and early treatment variables predicting the result of the IFN beta therapy in MS patients.
Results: Age, gender, duration of the disease, the total or annual number of relapses and disability scale status prior to the treatment did not prognosticate the response to the IFN beta treatment. In the pre-treatment period responders compared with non-responders underwent the RR course more often. The earlier initiation of the IFN beta treatment showed a positive predictive value but only in selected patients. During the first 2 years of treatment the absence of relapses, decreased disability scale status, neuroimages with 0-2 new T2 – related lesions, without active T1-related enhanced lesions and with lower T2-, T1- related lesions predicted beneficial effects after further 2-3 years of treatment.
Conclusion: A composite of selected predictors increases the chance of the beneficial IFN beta treatment outcome. The composite consists of the reduced number of relapses, the diminished disability scale status, the limited volume of new or extending T2-, T1- related lesions and the decreased number of active enhanced lesions during the first 2 years of treatment.
Downloads
References
Dhib-Jalbut S., Marks S. : Interferon- – mechanism of action in multiple sclerosis. Neurology 2010; 74, supl. 1, s. S17-S24.
Mitsdoerfer M., Kuchroo V.: How does interferon- really works in multiple sclerosis? Ann. Neurol. 2009; 65: 487-488.
PRISMS-4: Long-term efficacy of interferon- -1a in relapsing MS. Neurology 2001; 56: 1628-1636.
Jacobs L. Cookfair D., Rudick R. i wsp.: Intramuscular interferon beta – 1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 1996; 39: 285-294.
Kappos L., Freedman M., Polman C. i wsp.: Effect of early vs. delayed interferon beta – 1b treatment of disability after first clinical event suggestive of MS: a 3 – year follow-up analysis of the BENEFIT study. Lancet 2007; 370: 389-397.
Freedman M., Patry D., Grand’ Maison F. i wsp. Treatment optimization in multiple sclerosis. Can J. Neurolo. Sci. 2004; 31: 157-168.
Walansky L., Cook S., Skurnick J. i wsp. Betaferon vs. Copaxone in MS with triple-dose gadolinium and 3-T MRI Endpoints (BECOME): announcement on final primary study outcome. Multiple Sclerosis 2007; 13: suppl. 2, S 58.
Cendrowski W.: Ryzyko zmniejszonej skuteczności interferonu beta u chorych na stwardnienie rozsiane przyjmujących leki uzupełniające Neurol. Prakt. 2008; 8/5: 6-11.
O’Brien M., Longan R., Coselloe L. i wsp.: OAS genotype predicts responsiveness to beta – interferon therapy. Multiple Sclerosis 2008; 14: suppl. 1, S 194 – S 195.
Drulovic J., Savic E., Pekmezovic T. i wsp.: T-bet mRNA as a potential prognostic marker of treatment response to IFN- in RRMS. Multiple Sclerosis 2009; 15: suppl. 2, S 236.
Waubant E., Vukusic E. Ginoux L. i wsp.: Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003; 61: 184-189.
Rudick R., Lee J.-Ch. Simon J. i wsp.: Defining interferon response status in multiple sclerosis patients. Ann Neurol. 2004; 56: 548-555.
Peterit H. Nolden S., Schoppe S. i wsp.: Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon-beta treated MS patients. Multiple Sclerosis 2002; 8: 492-494.
Rio J., Nos C., Tintoré M. i wsp.: Defining the response to interferon- in RR MS patients. Ann. Neurol. 2006; 59: 344-352.
Bosca I., Coret F., Valero C. i wsp.: Effectof relapses over early progression of disability in MS patients treated with beta-interferon. Multiple Sclerosis 2008; 14: 636-639.
Rudick R., Lee J.-Ch., Bermel R. i wsp.: Predictors of long-term disability in RRMS: 8- and 15-year analyses from the phase 3 clinical trial of intramuscular interferon beta – 1a. Multiple Sclerosis 2008; 14: supl. 1, S 176.
Rio J., Rovira A., Tintore M. i wsp.: Relationship between MRI lesion activity and response to IFN- in RRMS patients. Multiple Sclerosis 2008; 14: 479-484.
Debouverie M., Vandenberghe H., Morrisey S. i wsp.: Predictive parameters of mitoxantrone effectiveness in the treatment of MS. Multiple Sclerosis 2004; 10: 407-412.
Munschauer F., Giovannoni G., Lublin F. i wsp.: Natalizumab significantly increases the cumulative probability of sustained improvements in physical disability. Multiple Sclerosis 2008; 14: supl. 1, S 167-S 168.
Schmit E., Gourraud P., Coutourier N. i wsp.: Early prediction of the long-term response to IFN beta in RRMS patients. Multiple Sclerosis 2007; 13: suppl. 2, S 58-S 59.
Comabella M., Rio J., Espejo C. i wsp.: Changes in matrix metalloproteinases and their inhibitors during interferon beta treatment in multiple sclerosis. Clin. Immunol. 2009; 130: 145-150.
Rio J., Rovira A., Huerga E. i wsp.: Clinical and MRI measures in the assessment of the response to interferon beta. Multiple Sclerosis 2008: 14: supl. S 175.
Cutter G., Sormani M., Simon J. i wsp.: A clinical – MRI composite score predictive of longer outcome in RRMS. Neurology 2009; 72: supl. 3, A 408.
Gajofatto A., Bacchetti P., Grimes B. i wsp. : Demographic and clinical predictors of response to interferon beta and glatiramer acetate as first-line treatment for RRMS. Multiple Sclerosis 2007; 13: suppl. 2, S 57 – S 58.
Karabudak R., Kurne A., Avdin Ö. i wsp.: Clinical differences between responders and non-responders to interferon beta treatment in MS. Multiple Sclerosis 2007; 13: suppl. 2, S 51 – S 52.
Rudick R., Lee J.-C. Zhang H. i wsp.: Progression of disability at 2 years predicts disability at 8 years in relapsing MS: analysis from the phase 3 clinical trial of intramuscular interferon beta- 1a. Multiple Sclerosis 2007; 13: suppl. 2, S 54.
Trojano M., Amato M., Avolio C., i wsp. : Heteregenous impact of an early IFN beta treatment on disability progression in RRMS subgroups with different baseline clinical profiles. Multiple Sclerosis 2007; 13: suppl. 2, S 59.
Bojko A., Davidowskaya M., Deomina T. i wsp.: MS course In RRMS and SPMS patients on IFN beta-1b treatment for At least 3 years: data from a Mocsow cantre. Multiple Sclerosis 2005; 11: suppl. 1, S 82.
Cendrowski W.: BENEFIT, CHAMPS i ETOMS: porównanie wyników leczenia intrerferonem beta chorych na kliniczne izolowane zespoły sugerujące stwardnienie rozsiane. Aktualności Neurol. 2006; 6: 195-199.
Kinkel R., Pace A., Simon J. i wsp. : Early MRI activity during IFN beta-1a therapy predicts disease activity at 5 years in patients at high risk for developing CDMS. Multiple Sclerosis 2009; 15: suppl. 2, S 129.
Maraal B., Pohl Ch., Vitdehaag B., i wsp.: Baseline MRI predictors for conversion to CDMS and Mc Donald multiple sclerosis based on integrated 3-year data from the BENEFIT study. Multiple Sclerolosis 2008; 14: suppl. 1, S 19.
Sandberg-Wollheim M. on behalf of the the PRISMS Study Group: The relationship between MRI lesion activity, relapses and disability progression in RRMS: a post-hoc analysis from the PRISMS study. Multiple Sclerosis 2005; 11: supl. 1, S 154.
Giuni E., Paolielo A., Tomassini V. i wsp.: An active scan at 12th month of therapy is associated with a worse response to IFN beta over the subsequent five years of treatment in RRMS. Neurology 2004; 60: supl. 1 A 251-A 252.
Elskamp I., Lembcke J., Dattolo V. i wsp.: Persistent T1 hypointensivity as an MRI marker for treatment efficacy in MS. Multiple Sclerosis 2008; 14: 764 – 769.
Traboulsee A., Zhao Y., Li D.: Composite MRI score as a biomarker in clinical trials in MS. Neurology 2006; 66: suppl. 2, A73 – A74.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2013 Medical Journal of the Rzeszow University and the National Medicines Institute, Warsaw
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
